Secondary endpoints include endoscopic remission.

Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis Altheus Therapeutics, Inc. The primary endpoint of ZA201 is reduction in the Ulcerative Colitis Disease Activity Index at 6 weeks . Secondary endpoints include endoscopic remission, decrease in UCDAI at 3 weeks, and time to resolution of anal bleeding; there are additional exploratory endpoints. In April 2014 Topline outcomes will be available. Related StoriesExpanded use for IntelliCap with further CE Tag for aspiration of fluidsImproving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts PharmaLiposomal sizing and the Coulter principle: an interview with Professor Melvin E.

wanted effects

Also in Global Wellness news: U.S. Grant to Uganda; reproductive wellness in Philippines; counterfeit drugs U.S. Grants Uganda $246M In Aid TO BOOST Agricultural, Health Systems The U.S. Embassy in Uganda announced a grant of $246 million in new aid for enhancing the Uganda’s agricultural and wellness systems, Reuters reports. More than $170 million will be allocated to health insurance and education to combat the HIV/AIDS pandemic, fight tuberculosis, eradicate malaria, improve kid and maternal health and increase access to family planning and reproductive wellness services, the news service writes . Roughly $35 million will be used to expand economic possibilities for farmers, encourage investment and trade, promote personal sector competitiveness, and help out with environment conservation, New Vision/ reviews .

Other Posts From "oncology":

Related Posts